Nutritional Implications of Tivicay (Dolutegravir)
Tivicay can be taken with or without food, and food actually increases its absorption—but products containing polyvalent cations (calcium, iron, magnesium, aluminum) found in antacids and multivitamins can significantly reduce dolutegravir absorption and must be separated from dosing.
Food Effects on Absorption
According to the FDA label, food enhances dolutegravir absorption rather than impairing it 1. Specifically:
- Low-fat meals increase AUC by 33% and Cmax by 46%
- Moderate-fat meals increase AUC by 41% and Cmax by 52%
- High-fat meals increase AUC by 66% and Cmax by 67%
Food also slows absorption, prolonging time to peak concentration from 2 hours (fasted) to 3-5 hours (fed). However, this food effect is not clinically significant for dosing—the drug can be administered with or without meals 2, 3.
Critical Drug-Nutrient Interactions
Polyvalent Cation-Containing Products
The most important nutritional consideration is avoiding concurrent administration with products containing aluminum, calcium, iron, or magnesium 4. These cations:
- Bind to integrase strand transfer inhibitors (INSTIs) like dolutegravir
- Reduce absorption of the medication
- Are commonly found in:
- Antacids
- Multivitamins
- Mineral supplements
- Some fortified foods
Practical management: Separate dolutegravir dosing from these products by several hours. Obtain a complete medication history including over-the-counter products, vitamins, minerals, and herbal remedies before prescribing 4.
Enteral Nutrition Considerations
For critically ill patients receiving enteral feeds, temporal spacing from feeding is recommended but may not fully prevent reduced drug concentrations 5. A 2025 case series found:
- All dolutegravir Cmax values were lower than expected (below 3340-3670 ng/mL)
- Six of eight trough concentrations were below the minimum effective concentration of 300 ng/mL
- Multiple factors in critical illness (delayed gastric emptying, altered gastric pH) likely contribute beyond just cation chelation
For ICU patients on enteral feeds: Consider therapeutic drug monitoring and frequent viral load checks, as standard spacing recommendations may be insufficient 5.
Weight and Metabolic Effects
Weight Gain Profile
Dolutegravir is associated with clinically significant weight gain, which represents an important nutritional consideration for long-term management:
- 18% of patients experienced ≥10% weight gain at 48 weeks in a South African cohort 6
- Average weight gain was 1.46 kg/year after transitioning to TLD (tenofovir/lamivudine/dolutegravir), compared to 0.35 kg/year before the switch 7
- Patients on TLD had 1.77 times the hazard of developing BMI ≥25 kg/m² compared to those on non-TLD regimens 7
Body Composition Changes
Beyond total weight, dolutegravir affects fat distribution 8, 9:
- Trunk fat and trunk/body fat ratio markedly increased after 12 months in adolescents 8
- Higher dolutegravir concentrations were negatively associated with visceral adipose tissue mass (paradoxically) 9
- These changes may increase future cardiovascular risk despite improvements in lipid profiles 8
Dietary Interventions Have Limited Impact
Importantly, lifestyle modifications appear insufficient to prevent dolutegravir-associated weight gain 6. A 48-week prospective study found:
- No significant differences in fruit, vegetable, fast food, fried food, or sugar-sweetened beverage intake between those with and without clinically significant weight gain
- No dietary or physical activity behaviors correlated with weight change in multivariable models
- Mean change in fruit intake was slightly higher in those gaining weight, but this was not clinically meaningful
Clinical implication: While healthy diet counseling remains important for overall health, interventions targeting diet and exercise are unlikely to mitigate dolutegravir-associated weight gain 6. This represents a medication effect rather than a behavioral issue.
Nutritional Status Monitoring
Baseline and Ongoing Assessment
Nearly all patients on dolutegravir demonstrate poor to intermediate diet quality, characterized by 10:
- Low intake of fresh foods
- High consumption of ultra-processed items
- No correlation between diet quality and nutritional status
Among Brazilian patients on DTG-based therapy 10:
- 48% were overweight
- 24.3% had abdominal obesity
- Most women had abdominal obesity despite most men being of normal weight
Monitoring Recommendations
Regular nutritional monitoring should include:
- Weight and BMI at each visit (at minimum every 6 months per PrEP guidelines, though more frequent for treatment) 3
- Waist circumference to assess central adiposity 7
- Baseline weight and BMI before initiating therapy to track changes 10
- Assessment of psychosocial and structural determinants affecting nutrition, not just dietary intake 10
Special Populations
Older Adults and Those with Comorbidities
Overweight and obesity are more common among 10:
- Older individuals
- Those with higher baseline BMI
- Lower education levels (for abdominal obesity)
- Lower CD4+ T-cell counts (for abdominal obesity)
Women
Women face disproportionate risk: Most women in studies had abdominal obesity despite most men being of normal weight 10. This sex difference requires particular attention to metabolic monitoring in women on dolutegravir.
Practical Clinical Approach
Before initiating dolutegravir:
- Document baseline weight, BMI, and waist circumference
- Review all supplements, vitamins, and over-the-counter medications
- Counsel that food enhances absorption (can take with meals)
- Warn about separating from cation-containing products
During treatment:
- Monitor weight and body composition regularly
- Set realistic expectations that diet/exercise may not prevent weight gain
- Focus nutritional counseling on overall health rather than weight prevention
- Consider metabolic screening for cardiovascular risk factors
For problematic weight gain:
- Recognize this as a medication effect, not patient non-compliance
- Consider alternative regimens if weight gain is excessive or causing metabolic complications
- Continue standard cardiovascular risk reduction strategies